Recognizing the widespread and devastating nature of the opioid crisis, AMCP formed the Addiction Treatment Advisory Group in 2015 based on the recommendation from the AMCP Partnership Forum, Breaking the Link between Pain Management and Opioid Use Disorder. The purpose of the advisory group was multifaceted and included a focus on gaining insight for managed care organizations to use to improve access to medications for treatment of substance use disorders. This group was composed of 19 national leaders from a wide range of organizations, including behavioral health organizations, outpatient treatment centers, nonprofit advocacy groups, health plans, pharmacy benefit management companies, specialty pharmacies, employers, hospitals and manufacturers. This group has now folded and its work incorporated into existing committees.
Read our list of the members of the ATAG here.
| The Role of Managed Care Pharmacy in Improving Access to Naloxone: A Viewpoint Article and Findings from the Addiction Treatment Advisory Group were formally published as an outsert with the December 2016 issue of the Journal of Managed Care & Specialty Pharmacy. |
 | Findings and Considerations for the Evidence-Based Use of Medications Used in the Treatment of Substance Use Disorder: A Viewpoint Article and Findings from the Addiction Treatment Advisory Group were formally published as an outsert with the December 2016 issue of the Journal of Managed Care & Specialty Pharmacy. |
 | AMCP Addiction Treatment Advisory Group Releases Findings on Improving Treatment of Opioid Addiction |
 | Overview of the Partnership to Amend 42 CFR Part 2: A coalition of over 20 health care stakeholders committed to aligning 42 CFR part 2 (part 2) with HIPAA to allow appropriate access to patient information that is essential for providing whole-person care. |
| AMCP Addiction Treatment Advisory Group to Identify Barriers, Improve Access to Treatment Services |
The AMCP ATAG provided input and guidance to staff as they developed comments, analysis and testimony to Congress and other federal and state agencies on how proposed regulations and laws associated with opioid use disorder.
AMCP Comments on the impact of the final rule for SAMHSA- 4162-20: Confidentiality of Substance Use Disorder Patient Records; November 3, 2016
AMCP comment to the Senate Finance Committee Hearing – Examining the Opioid Epidemic: Challenges and Opportunities; February 22, 2016
AMCP comments to the Centers for Disease Control’s Proposed 2016 Guideline for Prescribing Opioids for Chronic Pain (Docket Number CDC-2015-0112); January 16, 2016.
.jpg "AMCP Webinar Jpeg") | The ATAG has worked to develop educational programs to help inform and educate stakeholders on the myriad issues associated with opioid use disorder. AMCP members can access webinar content on the management of opioids and reducing misuse and abuse at the links provided below. |
 | AMCP has also developed the following continuing education program which provides 1.25 CEUs and reviews the landscape of current opioid addiction treatments and explore challenges and opportunities in patient access to appropriate treatment for acute episodes and chronic pain maintenance: |
There are a number of helpful resources that may be of use to individuals interested in this topic.
The work of the ATAG was supported by Alkermes, kaleo, and Precision Diagnostics.
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
